New drug could unblock Crohn's-Related bowel narrowing without surgery

NCT ID NCT07683325

Not yet recruiting Disease control Sponsor: Agomab Spain S.L.U. Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called ontunisertib in people with Crohn's disease who have developed scarred, narrowed sections in their bowel that cause pain and blockages. The goal is to see if the drug can reopen these narrowed areas, potentially reducing symptoms and the need for surgery. Participants will take the drug or a placebo for up to a year, with regular check-ups to monitor changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ontunisertib (AGMB-129)
What this could lead to: If successful, this drug could offer a non-surgical option to open narrowed sections of the bowel, reducing pain and the need for surgery in people with fibrostenosing Crohn's disease.
What could go wrong: This is a mid-stage trial, so the drug may not prove effective or safe enough. Side effects are possible, and results may not apply to all patients with Crohn's strictures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates